Thromboembolic consequences of subtherapeutic anticoagulation in patients stabilized on warfarin therapy: The low INR study

Pharmacotherapy

Volumn 28, Issue 8, 2008, Pages 960-967

  Clark, Nathan P ^a,g   Witt, Daniel M ^a   Delate, Thomas ^b   Trapp, Melissa ^a   Garcia, David ^c   Ageno, Walter ^d   Hylek, Elaine M ^e   Crowther, Mark A ^f  

^a Clinical Pharmacy Anticoagulation Service   (United States)

^b Kaiser Permanente Colorado   (United States)

^c UNIVERSITY OF NEW MEXICO HEALTH SCIENCES CENTER   (United States)

^d UNIVERSITY OF INSUBRIA   (Italy)

^e BOSTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^f MCMASTER UNIVERSITY   (Canada)

^g KAISER PERMANENTE   (United States)

Author keywords

Anticoagulation management; Bridge therapy; INR; International normalized ratio; Subtherapeutic anticoagulation; Thromboembolism; Thrombosis; Vitamin K antagonist; Warfarin

Indexed keywords

ANTIVITAMIN K; HEPARIN; NIFEDIPINE; WARFARIN;

ADULT; AGED; ANTICOAGULATION; ARTICLE; BLEEDING; COHORT ANALYSIS; CONTROLLED STUDY; DRUG EFFECT; DRUG EFFICACY; EMBOLISM; FEMALE; HUMAN; INTERNATIONAL NORMALIZED RATIO; LONGITUDINAL STUDY; MAJOR CLINICAL STUDY; MALE; OUTCOME ASSESSMENT; RETROSPECTIVE STUDY; RISK ASSESSMENT; RISK FACTOR; THROMBOEMBOLISM; UNITED STATES;

ADULT; AGED; ANTICOAGULANTS; COHORT STUDIES; FEMALE; HUMANS; INTERNATIONAL NORMALIZED RATIO; MALE; MIDDLE AGED; RETROSPECTIVE STUDIES; THROMBOEMBOLISM; WARFARIN;

EID: 48249123814     PISSN: 02770008     EISSN: None     Source Type: Journal    
DOI: 10.1592/phco.28.8.960     Document Type: Article

References (24)

1. Hutten BA, Prins MH. Duration of treatment with vitamin K antagonists in symptomatic venous thromboembolism. Cochrane Database Syst Rev 2006;(1):CD001367.
2. Anand SS, Yusuf S. Oral anticoagulant therapy in patients with coronary artery disease: a meta-analysis. JAMA 1999;282:2058-67.
3. Meade TW, Wilkes HC, Kelleher CC, et al. Thrombosis prevention trial: randomised trial of low-intensity oral anticoagulation with warfarin and low-dose aspirin in the primary prevention of ischaemic heart disease in men at high risk. Lancet 1998;351:233-41.
4. van Walraven C, Hart RG, Singer DE, et al. Oral anticoagulants vs aspirin in nonvalvular atrial fibrillation: an individual patient meta-analysis. JAMA 2002;288:2441-8.
5. Schulman S, Granqvist S, Holmstrom M, et al. The duration of oral anticoagulant therapy after a second episode of venous thromboembolism. N Engl J Med 1997;336:393-8.
6. Witt DM, Sadler MA, Shanahan RL, Mazzoli G, Tillman DJ. Effect of a centralized clinical pharmacy anticoagulation service on the outcomes of anticoagulant therapy. Chest 2005;127:1515-22.
7. Gurwitz JH, Field TS, Radford MJ, et al. The safety of warfarin therapy in the nursing home setting. Am J Med 2007;120:539-44.
8. Reynolds MW, Fahrbach K, Hauch O, et al. Warfarin anticoagulation and outcomes in patients with atrial fibrillation: a systematic review and meta-analysis. Chest 2004;126:1938-45.
9. Hylek EM, Evans-Molina C, Shea C, Henault LE, Regan S. Major hemorrhage and tolerability of warfarin in the first year of therapy among elderly patients with atrial fibrillation. Circulation 2007;115:2689-96.
10. Booth SL, Charnley JM, Sadowski JA, et al. Dietary vitamin K1 and stability of oral anticoagulation: proposal of a diet with constant vitamin K1 content. Thromb Haemost 1997;77:504-9.
11. O'Reilly RA, Rytand DA. "Resistance" to warfarin due to unrecognized vitamin K supplementation. N Engl J Med 1980;303:160-1.
12. Holbrook AM, Pereira JA, Labiris R, et al. Systematic overview of warfarin and its drug and food interactions. Arch Intern Med 2005;165:1095-106.
13. Cropp JS, Bussey HI. A review of enzyme induction of warfarin metabolism with recommendations for patient management. Pharmacotherapy 1997;17:917-28.
14. Hylek EM, Skates S, Sheehan M, Singer DE. An analysis of the lowest effective intensity of prophylactic anticoagulation for patients with nonrheumatic atrial fibrillation. N Engl J Med 1996;335:540-6.
15. Kovacs MJ, Kearon C, Rodger M, et al. Single-arm study of bridging therapy with low-molecular-weight heparin for patients at risk of arterial embolism who require temporary interruption of warfarin. Circulation 2004;110:1658-63.
16. Douketis JD, Johnson JA, Turpie AG. Low-molecular-weight heparin as bridging anticoagulation during interruption of warfarin. Arch Int Med 2004;164:1319-26.
17. Palareti G, Manotti C, D'Angelo A, et al. Thrombotic events during oral anticoagulant treatment: results of the inception-cohort, prospective, collaborative ISCOAT study. Thromb Haemost 1997;78:1438-43.
18. Oake N, Fergusson DA, Forster AJ, van Walraven C. Frequency of adverse events in patients with poor anticoagulation: a meta-analysis. Can Med Assoc J 2007;176:1589-94.
19. Palareti G, Legnani C, Cosmi B, et al. Poor anticoagulation quality in the first 3 months after unprovoked venous thromboembolism is a risk factor for long-term recurrence. J Thromb Haemost 2005;3:955-61.
20. Naranjo CA, Busto U, Sellers EM, et al. A method for estimating the probability of adverse drug reactions. Clin Pharmacol Ther 1981;30:239-45.
21. Stroke Prevention in Atrial Fibrillation Investigators. Adjusted-dose warfarin versus low-intensity, fixed-dose warfarin plus aspirin for high-risk patients with atrial fibrillation: stroke prevention in atrial fibrillation III randomised clinical trial. Lancet 1996;348:633-8.
22. Salem DN, Stein PD, Al-Ahmad A, et al. Antithrombotic therapy in valvular heart disease: native and prosthetic. The seventh ACCP conference on antithrombotic and thrombolytic therapy. Chest 2004;1236:S457-82.
23. Kearon C, Ginsberg JS, Kovac MJ, et al. Comparison of low-intensity warfarin therapy with conventional-intensity warfarin therapy for long-term prevention of recurrent thromboembolism. N Engl J Med 2003;349:631-9.
24. Tillman DJ, Charland SL, Witt DM. Effectiveness and economic impact associated with a program for outpatient management of acute deep vein thrombosis in a group model health maintenance organization. Arch Intern Med 2000;160:2926-32.